February 24, 2020 First fragile X test is approved, and Zynerba could benefit The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
July 05, 2017 Biotech floats come back with a vengeance The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
